Checked
Leukemia Clinical Trials in Illinois
Open studies with at least one site in the state
Study listings come from ClinicalTrials.gov, where sponsors register and update their own studies. A listing does not mean a study is safe or effective, and DatenUS does not recommend any study. Talk with your doctor before joining a clinical trial, and use ClinicalTrials.gov for contact details and full eligibility rules.
- Open studies
- 92
- With a site in Illinois
- Most studies in
- Chicago
- 44 of the studies shown
Studies
50 of 92, recruiting studies first. Cities are where the study lists a Illinois site.
- Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL StudyRecruitingPhase 3NCT04269902· National Cancer Institute (NCI)
Springfield, Chicago, Decatur, Effingham and 36 more
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT05554393· National Cancer Institute (NCI)
Springfield, Chicago, Decatur, Centralia and 8 more
- Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT05554406· National Cancer Institute (NCI)
Peoria, Springfield, Bloomington, Chicago and 21 more
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)RecruitingPhase 2NCT05564390· National Cancer Institute (NCI)
Chicago, Peoria, Springfield, Bloomington and 36 more
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT06317649· National Cancer Institute (NCI)
Chicago, Springfield, Decatur, Effingham and 17 more
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT06672146· National Cancer Institute (NCI)
Chicago, Glenview, Orland Park, DeKalb and 9 more
- Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple MyelomaRecruitingPhase 2NCT06517017· University of Utah
Chicago
- A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)RecruitingPhase 3NCT06943872· BeOne Medicines
Chicago, Niles
- A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)RecruitingPhase 1, Phase 2NCT06969430· Debiopharm International SA
Chicago
- A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid LeukemiaRecruitingPhase 1NCT07012044· National Cancer Institute (NCI)
Chicago
- Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX OverexpressionRecruitingPhase 1, Phase 2NCT07155226· AstraZeneca
Decatur
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged LeukemiaRecruitingPhase 2NCT06317662· National Cancer Institute (NCI)
Chicago, Oak Lawn, Park Ridge, Peoria and 1 more
- Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)RecruitingPhase 2NCT07437950· National Cancer Institute (NCI)
Springfield, Decatur, Bloomington, Canton and 11 more
- Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group StudiesRecruitingNCT00736749· Children's Oncology Group
Chicago, Maywood, Oak Lawn, Peoria and 1 more
- Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and CareRecruitingNCT05745285· University of Miami
Chicago
- A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell MalignanciesRecruitingPhase 1NCT06528301· Umoja Biopharma
Chicago
- Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic LeukemiaRecruitingPhase 1, Phase 2NCT07109219· AstraZeneca
Chicago
- AZD0486 as Monotherapy in B-cell Acute Lymphoblastic LeukaemiaRecruitingPhase 1, Phase 2NCT06137118· AstraZeneca
Chicago
- Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaRecruitingPhase 2NCT06918431· City of Hope Medical Center
Chicago
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationRecruitingPhase 1, Phase 2NCT04065399· Syndax Pharmaceuticals
Chicago
- A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)RecruitingPhase 1NCT06173518· Autolus Limited
Chicago
- Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)RecruitingPhase 3NCT07223814· Stichting Hemato-Oncologie voor Volwassenen Nederland
Chicago
- Screening Study for KIT D816V Mutated Mast Cell Disease in Select PopulationsRecruitingNCT07143669· Blueprint Medicines Corporation
Evanston, Normal
- Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)RecruitingPhase 3NCT07509151· AstraZeneca
Chicago
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingPhase 1, Phase 2NCT05006716· BeOne Medicines
Zion
- Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer DetectionRecruitingNCT05334069· Alliance for Clinical Trials in Oncology
Chicago, Springfield, Aurora, Bloomington and 36 more
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLRecruitingPhase 3NCT07321652· Alliance for Clinical Trials in Oncology
Springfield, Chicago, Decatur, Normal and 20 more
- Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic SyndromesRecruitingPhase 1NCT06484062· National Cancer Institute (NCI)
Chicago, New Lenox, Orland Park
- A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaRecruitingPhase 3NCT06973187· BeOne Medicines
Chicago
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3NCT07277231· BeOne Medicines
Chicago, Zion
- A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)RecruitingPhase 3NCT06852222· Janssen Research & Development, LLC
Chicago, Niles
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 MutationsRecruitingPhase 3NCT04293562· Children's Oncology Group
Chicago, Maywood, Oak Lawn, Park Ridge and 2 more
- A Study of Venetoclax in Combination With Conventional Chemotherapy in Pediatric Patients With Acute Myeloid LeukemiaRecruitingPhase 2NCT05955261· St. Jude Children's Research Hospital
Chicago
- (Apex) Bezuclastinib in Patients With Advanced Systemic MastocytosisRecruitingPhase 2NCT04996875· Cogent Biosciences, Inc.
Chicago
- Daratumumab for Chemotherapy-Refractory Minimal Residual Disease in T Cell ALLRecruitingPhase 2NCT05289687· Eastern Cooperative Oncology Group
Chicago
- Study of Olverembatinib (HQP1351) in Patients With CML-CPRecruitingPhase 3NCT06423911· Ascentage Pharma Group Inc.
Chicago, Decatur
- A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic LeukemiaRecruitingPhase 1, Phase 2NCT05849662· Therapeutic Advances in Childhood Leukemia Consortium
Chicago
- Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid LeukemiaRecruitingPhase 3NCT07022678· Children's Oncology Group
Chicago
- Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AMLRecruitingPhase 1, Phase 2NCT04588922· Sellas Life Sciences Group
Zion
- Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1, Phase 2NCT07284433· AvenCell Therapeutics, Inc.
Chicago, Evanston
- Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLyRecruitingPhase 3NCT03959085· Children's Oncology Group
Chicago, Maywood, Oak Lawn, Park Ridge and 3 more
- The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group StudyRecruitingPhase 1, Phase 2NCT04726241· PedAL BCU, LLC
Chicago, Maywood, Oak Lawn, Park Ridge and 3 more
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseRecruitingPhase 1NCT05886049· National Cancer Institute (NCI)
Chicago
- A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to TherapyRecruitingPhase 1NCT06247787· Children's Oncology Group
Chicago
- Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)RecruitingPhase 3NCT05183035· PedAL BCU, LLC
Chicago
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaRecruitingPhase 1NCT06001788· Kura Oncology, Inc.
Chicago, Maywood, Springfield
- Caloric Restriction and Activity to Reduce Chemoresistance in B-ALLRecruitingPhase 2NCT05082519· Etan Orgel
Chicago
- A Study of CTD402 in T-ALL/LBL PatientsRecruitingPhase 1, Phase 2NCT07070219· Imviva Bio
Chicago
- Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven TreatmentRecruitingNCT06274788· Fresenius Kabi
Chicago
- ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLLRecruitingPhase 3NCT07342478· Newave Pharmaceutical Inc
Skokie
Other cancer studies in Illinois
Frequently asked questions
- Are there leukemia clinical trials in Illinois?
- Yes. 92 leukemia studies on ClinicalTrials.gov list at least one site in Illinois and are recruiting, about to recruit or enrolling by invitation, including sites in Chicago, Springfield, Peoria.
- What does recruiting mean?
- Recruiting means the study is currently enrolling participants. Not yet recruiting means it has been registered but has not started enrolling. Enrolling by invitation means participants are selected by the study team rather than through open enrollment.
- How do I join a clinical trial?
- Read the full eligibility criteria and contact information on ClinicalTrials.gov, then talk with your doctor about whether a study may be right for you. The study team decides who can enroll.
Source: ClinicalTrials.gov, National Library of Medicine · Last updated 10/26/2026